Stuart Wood PhD
VP, Discovery Technology
Stuart has held a series of leadership roles in Biotech for over ten years, most recently as Chief Technology Officer at Nanna Therapeutics. Across his roles, Stuart has worked to develop novel solid state nanopore sequencing systems, and applied microfluidic solutions to increase throughput of a range of biochemical and cellular assay systems. More recently at Nanna, Stuart developed a microdroplet screening platform for natural products and medicinal chemistry approaches which underpinned the building of the technology platforms and therapeutic areas at Nanna.
As Nanna grew from two to over twenty staff, Stuart was central to the build of the company and development of early therapeutic programs to tackle mitochondrial dysfunction with application in rare diseases and neurodegeneration in partnership with clinical and academic groups through to the company’s acquisition in 2020 by Astellas.
Stuart began his scientific career working on bacterial genetics & biochemistry studying DNA repair and homologous recombination. He moved to Cambridge to undertake a career development fellowship at the MRC Mitochondrial Biology Unit. Here he studied how errors in mitochondrial DNA replication and transcription led to human disease, developing novel techniques to study mitochondrial nucleic acids.